Hims & Hers Health, Inc. (HIMS) - 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2024. Hims & Hers Health, Inc. operates a consumer-first digital health platform providing telehealth consultations, prescription fulfillment, and wellness products. The company focuses on sexual health, hair loss, dermatology, mental health, and weight loss. In 2024, the company achieved its first full year of GAAP profitability.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $1,476.5 million | $872.0 million | +69% |
| Net Income | $126.0 million | ($23.5 million) loss | Turnaround to Profit |
| Adjusted EBITDA | $176.9 million | $49.5 million | +257% |
| Free Cash Flow | $198.3 million | $47.0 million | +320% |
| Gross Margin | 79% | 82% | -300 bps |
| Cash & Equivalents | $220.6 million | $96.7 million | +128% |
| Subscribers (End of Period) | 2.23 million | 1.54 million | +45% |
Debt & Liquidity: As of December 31, 2024, the company held no long-term debt. In February 2025, the company secured a new $175 million senior secured revolving credit facility.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by the launch of weight loss offerings (GLP-1s) in late 2023 and 2024, which contributed significantly to Online Revenue growth of 71%.
- Profitability: The company transitioned from a net loss to net income, aided by a $68.0 million release of the valuation allowance on domestic deferred tax assets due to sustained tax profitability.
- Acquisitions: Acquired MedisourceRx (a 503B compounding facility) in September 2024 for approximately $31.0 million to expand compounding capabilities.
- Share Repurchases: Repurchased $83.0 million of Class A common stock in 2024 under its share repurchase programs.
Guidance, Outlook, and Risks
Outlook & Strategy: Management expects continued investment in growth, including facility expansion and marketing. The company anticipates seasonality in Q1 due to New Year's resolutions driving weight loss subscriptions. Future growth is targeted through specialty expansion (e.g., testosterone, menopause, sleep disorders) and international markets.
Key Risks & Contingencies:
- Regulatory Environment: Significant risk regarding the FDA's regulation of compounded GLP-1s. The FDA resolved the semaglutide shortage in February 2025, which may constrain the company's ability to offer compounded versions once current inventory is sold.
- Corporate Practice of Medicine: Reliance on Affiliated Medical Groups to provide clinical services creates regulatory risk regarding state laws prohibiting the corporate practice of medicine.
- Supply Chain: Dependence on single suppliers for certain newer offerings and potential disruptions in the global supply chain.
- Marketing Costs: Continued heavy investment in customer acquisition is required to maintain growth, impacting operating margins.
Investor Verification Checklist
- GLP-1 Sustainability: Verify the impact of the FDA resolving the semaglutide shortage on the company's ability to continue selling compounded weight loss products and the resulting margin implications.
- Deferred Tax Benefit: Confirm the sustainability of the $68 million tax benefit from the valuation allowance release and whether it is a one-time event.
- Customer Acquisition Costs (CAC): Monitor the trend of marketing expenses as a percentage of revenue to ensure growth remains efficient as the subscriber base matures.
- Regulatory Compliance: Review ongoing FDA and state-level enforcement actions regarding telehealth and compounding practices.
- Debt Covenants: Assess the terms of the new $175 million credit facility and any leverage covenants that could restrict future operations.